In patients with nasopharyngeal carcinoma in remission after radiation-based treatment (327 of 353 evaluable), 3 years of EGCG did not significantly reduce EBV DNA reactivation or recurrence vs placebo; toxicity was minimal.
RCTn = 353
Tsai et al. A randomized trial to evaluate the effect of epigallocatechin gallate (EGCG) on EBV reactivation in patients with nasopharyngeal carcinoma in remission -the TCOG T2312 study